6, B). eRK) and (mTORC1 and DNA synthesis via an AMPK-independent system. Similar results had been attained with metformin utilized at dosages that induced either humble or pronounced reductions in intracellular ATP amounts, which were practically identical towards the reduces in ATP amounts attained in response to berberine. We suggest that metformin and berberine inhibit mitogenic signaling in PDAC cells through Hoechst 33258 dose-dependent AMPK-dependent and independent pathways. == Launch == Pancreatic ductal adenocarcinoma (PDAC) is certainly a damaging disease, with general 5-year survival price of just 6%[1]. The occurrence of the disease in america is estimated to improve to a lot more than 44,000 brand-new situations in 2014 and is currently the 4th leading cause of cancer mortality in both men and women[2]. Total deaths due to PDAC are projected to increase dramatically to become the second leading cause of cancer-related deaths before 2030[1]As the current therapies offer very limited survival benefits, novel strategies to treat and prevent this aggressive disease are urgently required[3]. G protein-coupled receptors (GPCRs) and their cognate agonists are increasingly implicated as autocrine/paracrine growth factors for multiple solid tumors, including small cell lung cancer, colon, prostate, breast and pancreas[4][8]. We showed that pancreatic cancer cell lines express multiple GPCRs[9]and a variety of GPCR agonists, including neurotensin, angiotensin II and bradykinin, stimulated DNA synthesis in pancreatic cancer cell lines, including PANC-1 and MiaPaca-2[9][12]. Furthermore, a broad-spectrum GPCR antagonist[13],[14], inhibited the growth of pancreatic cancer cells eitherin vitroor xenografted into nu/nu mice[15]. Other studies demonstrated increased expression of GPCRs in pancreatic cancer tissues[16][19]. Subsequently, we identified positive crosstalk between insulin/IGFI receptors and GPCR signaling systems in pancreatic cancer cells, leading to mTORC1 signaling and ERK activation, and synergistic stimulation of DNA synthesis and cell proliferation[20][22]. These findings assume an added importance in view of the large number of epidemiological studies linking long standing type-2 diabetes mellitus (T2DM), obesity and metabolic syndrome, characterized by peripheral insulin resistance and compensatory overproduction of insulin, with increased risk for developing pancreatic cancer[23][32]. The biguanide metformin (1,1-dimethylbiguanide hydrochloride) derived from galegine, a Hoechst 33258 phytochemical fromGalega officinalis,is the most widely prescribed drug for treatment of T2DM,worldwide[33],[34]. Systemically, metformin lowers blood glucose levels through reduced hepatic gluconeogenesis, increases glucose uptake in skeletal muscles and adipose tissue[34], [35]and reduces the circulating levels of insulin and IGF-1[36],[37]. At the cellular level, metformin indirectly stimulates AMPactivated protein kinase (AMPK) activation[38]via inhibition of mitochondrial function, though other Hoechst 33258 mechanisms of metformin action have been also suggested at high doses[39]. Major downstream targets of AMPK include TSC2 and Raptor[40][43]. The AMPK-mediated phosphorylation of these targets inhibits mTOR complex 1 (mTORC1) activity in a variety of cell types, including PDAC cells[44],[45]and disrupts positive crosstalk between insulin/IGFI receptors and GPCR signaling systems[21],[46]. Interestingly, a number of observational studies suggest that metformin reduces incidence and improved prognosis of a variety of cancers in patients with T2DM[47],[48], though this this conclusion is under scrutiny[49]. In the setting of PDAC, diabetic patients who had received metformin appear to Hoechst 33258 have lower adjusted incidence and better survival compared with those who had not taken metformin or used other anti-diabetic agents[47],[50][52]. We hypothesized that structurally unrelated natural or synthetic compounds that interfere with mitochondrial-mediated ATP synthesis and target mTORC1 and ERK pathways, could provide novel anti-PDAC agents. Natural products represent a rich reservoir of potential small chemical molecules exhibiting diverse pharmacological properties. The isoquinoline alkaloid berberine[53][55], a FGF6 phytochemical extracted from a variety of medicinal plants, including plants of theBerberisspecies induces multiple biological effects, including anti-obesity, anti-diabetic, anti-cancer and calorie-restriction effects[55][62]. The cellular mechanism(s) involved, however, remains incompletely understood. Berberine has been reported to inhibit mitochondrial function and induce AMPK activation[63]but other mechanisms of action of this alkaloid have been proposed when added at high concentrations[64],[65]. Despite its potential clinical implications, there is no understanding of the precise mechanism(s) by which berberine inhibits the proliferation of cancer cells and it is not known whether this agent has any direct effect on signaling and proliferation of PDAC cells harboringKRASmutations, characteristic of >90% of ductal pancreatic carcinomas. In this study, we show that berberine inhibits DNA synthesis, cell cycle progression and proliferation in PANC-1 and.